粤港澳大湾区生物医药协同创新的对策建议  

Countermeasures and Suggestions for Collaborative Biomedical Innovation in the Guangdong-Hong Kong-Macao Greater Bay Area

作　　者：杨秋荣[1] YANG Qiurong(China Development Institute,518029,Shenzhen,Guangdong,China)

机构地区：[1]综合开发研究院(中国·深圳),广东深圳518029

出　　处：《特区经济》2024年第9期14-20,共7页Special Zone Economy

摘　　要：在粤港澳大湾区建设向纵深推进的背景下,生物医药协同创新成为大湾区产业高质量发展中非常重要的组成部分,同时也是大湾区打造具有全球影响力的国际科技创新中心的关键支撑。大湾区生物医药具有良好的产业基础,集聚优势突出,产业链较完整。同时,大湾区生物医药面临技术协同创新不足、要素跨境流动仍待进一步畅通,服务平台功能急需完善等制约因素,需要推动顶层政策制定、技术创新、科研成果转化、科研要素流动、服务体系等方面的协同创新,提升大湾区生物医药协同创新整体效能与全球竞争力。In the context of the in-depth construction of the Guangdong Hong Kong Macao Greater Bay Area,the collaborative innovation of biomedicine has become an integral part of the high-quality development of the Greater Bay Area's industry,as well as a crucial factor in the Greater Bay Area's efforts to establish an internationally renowned scientific and technological innovation center.The Greater Bay Area has a robust biomedical industry foundation,with significant advantages in the agglomeration and a generally full indus-trial chain.At the same time,facing constraints such as insufficient technological collaborative innova-tion,the cross-border flow of elements still needs to be further unblocked,and service platform functions need to be improved.It is necessary to promote collaborative innovation in top-level policy design,techno-logical collaboration,the transformation of scientific research achievements,service systemsand,and the flow of scientific technological elements,to improve the overall efficiency and global competitiveness of collaborative innovation in biological medicine in the Great Bay Area.

关 键 词：协同创新 粤港澳大湾区 要素跨境流动 

分 类 号：F426.72[经济管理—产业经济]